Clinical trial
Study in Participants With Early-Stage or Locally Advanced Human Epidermal Growth Factor Receptor (HER) 2-Positive and Estrogen Receptor/Progesterone Receptor Negative Breast Cancer to Evaluate the Efficiency and Safety of Treatment With Trastuzumab Plus (+) QL1209/Pertuzumab + Docetaxel.
NCT04629846
Study timeline
Study start (actual)2020-11-23Date precision: day
Registry last updated2024-04-19
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
TrastuzumabDRUG · verified · RxNorm: trastuzumab
QL1209DRUG
PertuzumabDRUG · verified · RxNorm: pertuzumab
DocetaxelDRUG · verified · RxNorm: docetaxel
surgeryPROCEDURE
Sponsors & collaborators
Qilu Pharmaceutical Co., Ltd.lead sponsor
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT04629846 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.